NCT04362735View on ClinicalTrials.gov

Efficacy of Vedolizumab in Crohn's Disease Patients Naive to Biological Therapy

UnknownOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

January 20, 2021

Study Completion Date

April 1, 2021

Conditions
Crohn Disease
Interventions
DRUG

Vedolizumab

Vedolizumab 300 mg at weeks 0, 2 and 6 as induction. Maintenance every 4 or 8 weeks, as on-label recommendations.

Sponsors

Collaborators (1)

Takeda
All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

Pontifícia Universidade Católica do Paraná

OTHER